Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alprostadil + WC3036 is a combination drug intended for the treatment of erectile dysfunction. Alprostadil is a synthetic analog of prostaglandin E1 (PGE1) that induces vasodilation and relaxation of smooth muscle in the corpus cavernosum primarily via increased cyclic AMP (cAMP) levels, facilitating penile erection. The mechanism of action for WC3036 is not explicitly documented in available sources; however, based on naming conventions and therapeutic context, it is likely a phosphodiesterase type 5 (PDE5) inhibitor, a class commonly paired with alprostadil to enhance erectile response in cases where monotherapy is insufficient. The rationale for such combinations is to exploit synergistic interactions between agents that modulate the cAMP and cGMP pathways. This combination is particularly used for men with erectile dysfunction refractory to first-line oral monotherapies, such as PDE5 inhibitors, or post-prostatectomy cases[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alprostadil + WC3036.